MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22 nd Annual Institutional Investor Conference | Minneapolis, MN 1:1 sessions: Wednesday, May 28, 2025 Goldman Sachs 46 th Annual Global Healthcare Conference | Miami, FL 1:1 sessions: Wednesday,... Read More

MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the BofA Securities 2025 Healthcare Conference in Las Vegas, NV. Presentation Details: Tuesday, May 13, 2025 5:15 p.m. PDT Webcast Link Investors interested in meeting with senior management at this event may contact their Bank of America... Read More

MARIETTA, Ga., May 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of its health economics data for reconstruction of cutaneous wounds with EPIFIX ® (Dehydrated Human Amnion Chorion Membrane, or DHACM) following Mohs surgery. The study has been published in the May 2025 issue of Journal of Drugs in Dermatology : “Placental allograft reconstruction of... Read More

Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025, at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc.... Read More

MARIETTA, Ga., April 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2025 after the market close on Wednesday, April 30, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.... Read More

MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions. “MIMEDX’s ongoing commitment to innovation and our expanding, best-in-class body of... Read More

MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45 th Annual Health Care Conference. TD Cowen's 45 th Annual Health Care Conference is taking place on March 3-5, 2025, at the Boston Marriott Copley Place in Boston, MA. The conference incorporates presentations, fireside chats and innovative... Read More

Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0.05, Respectively Fourth Quarter Adjusted EBITDA¹ was $20 Million, or 21% of Net Sales Management to Host Conference Call Today, February 26, 2025, at 4:30 PM ET MARIETTA, Ga., Feb. 26, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the... Read More

MARIETTA, Ga., Feb. 05, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2024 after the market close on Wednesday, February 26, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern... Read More

MARIETTA, Ga., Dec. 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has filed a lawsuit against Surgenex, LLC in the United States District Court for the District of Arizona. The complaint asserts that several of Surgenex’s placental allograft products infringe the Company’s patents and seeks permanent injunctive relief and monetary damages. This matter... Read More

MARIETTA, Ga., Dec. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Mizuho Health Care Conference Wednesday, December 11, 2024 1:1 sessions | New York, NY Northland Growth Conference Thursday, December 12, 2024 1:1 sessions | Virtual Stifel MedTech West Coast Bus Tour... Read More

Over 200 Unproven Skin Substitutes Will No Longer Be Covered Under Revised LCDs Company to Benefit from MACs’ Commitment to Clinically Effective, Proven Products MARIETTA, Ga., Nov. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following update on the Local Coverage Determinations (“LCDs”) regarding “Skin Substitute Grafts/Cellular and Tissue-Based Products for... Read More

MARIETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Stifel Healthcare Conference 2024 Webcast (9:45 AM ET): Click here to access Monday, November 18, 2024 New York, NY 15 th Annual Craig-Hallum Alpha Select Conference Tuesday, November 19, 2024 New York, NY... Read More

Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, Respectively Third Quarter Adjusted EBITDA was $18 Million, or 22% of Net Sales Raises 2024 Net Sales Growth Expectations to the High Single-Digits Management to Host Conference Call Today, October 30, 2024, at 4:30 PM ET MARIETTA, Ga., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MiMedx... Read More

MARIETTA, Ga., Oct. 14, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2024 after the market close on Wednesday, October 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same... Read More

MARIETTA, Ga., Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today highlighted the publication of a feature article on placental allografts for patients with hard-to-heal, acute and chronic wounds, which was published in today’s New York Times : “Her Face Was Unrecognizable After an Explosion. A Placenta Restored It.” The author underscored the benefits of placental... Read More

Company to Sponsor Lunch Symposium and Hands-On Skills Lab Featuring Seven Accepted Posters, Further Expanding Its Best-In-Class Portfolio of Clinical and Scientific Research MARIETTA, Ga., Oct. 01, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place October 2-5 in Las Vegas, NV. SAWC Fall... Read More

Ex-MiMedx Employee Jake Heikkinen Files Counterclaims Alleging Schemes 'To Bilk Medicare' and 'Incentivize and Pressure Healthcare Providers' per Mintz Attorneys MARIETTA, Ga. , Sept. 4, 2024 /PRNewswire/ -- The third of 10 defendants who were sued earlier this year by MiMedx Group, Inc. (NASDAQ: MDXG) today filed counterclaims against the company. Jake Heikkinen, a former MiMedx employee, states in the filing that he left... Read More

MARIETTA, Ga., Aug. 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Morgan Stanley 22 nd Annual Global Healthcare Conference Friday, September 6, 2024 New York, NY Lake Street 8 th Annual Big8 Best Ideas Growth Conference Thursday, September 12, 2024 Minneapolis, MN 2024... Read More

Ex-MiMedx Employee Caralyn Gargan Files Counterclaims for "Predatory Sales Practices" and "Incentivized Fraud" per Mintz Attorneys MARIETTA, Ga. , Aug. 26, 2024 /PRNewswire/ -- One of 10 defendants who were sued earlier this year by MiMedx Group, Inc. ( NASDAQ: MDXG) today filed counterclaims against the placental biologics company. Caralyn Gargan, a former MiMedx employee, filed the action against MiMedx for "predatory... Read More

MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the commercial launch of HELIOGEN™ Fibrillar Collagen Matrix, a particulate xenograft product aimed at addressing complex wounds primarily in the surgical setting. HELIOGEN is a shelf-stable offering that contains Type I and Type III collagen and mimics the native composition of structural connective... Read More

Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12, Respectively Second Quarter Adjusted EBITDA was $20 Million, or 23% of Net Sales Management to Host Conference Call Today, July 31, 2024, at 4:30 PM ET MARIETTA, Ga., July 31, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today... Read More

Study adds to the Company’s growing body of evidence and expands the understanding of the regulatory capabilities of its DHACM and LHACM allografts on the fibrotic process Marks MIMEDX’s first publication in the 5 th most-cited journal in the world MARIETTA, Ga., July 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the publication of a peer reviewed study... Read More

MARIETTA, Ga., July 17, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2024 after the market close on Wednesday, July 31, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.... Read More

MARIETTA, Ga., June 26, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointment of Kim Moller to Chief Commercial Officer. Ms. Moller has been serving as the Company’s Senior Vice President, Sales since August 2020. “I am pleased to announce this well-deserved promotion of Kim to Chief Commercial Officer for MIMEDX,” stated Joseph H. Capper, MIMEDX Chief... Read More

MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 21 st Annual Institutional Investor Conference Wednesday, May 29, 2024 Renaissance Minneapolis Hotel, The Depot 225 3 rd Avenue South Minneapolis, MN Northland Growth Conference 2024 Tuesday,... Read More

Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024, at 4:30 PM ET MARIETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first... Read More

MARIETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the first quarter ended March 31, 2024 after the market close on Tuesday, April 30, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day.... Read More

Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits and 2024 Adjusted EBITDA 1 Margin Above 20% MARIETTA, Ga., March 27, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or... Read More

MARIETTA, Ga., March 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has entered into an agreement with TELA Bio, Inc. to obtain exclusive rights to its manufacturing and supply agreement with Regenity Biosciences that will enable the Company to add xenograft products to its portfolio of Advanced Wound Care and Surgical solutions. Commenting on this... Read More

MARIETTA, Ga., March 04, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated records of executive leadership, strategic counsel and shareholder value... Read More

Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million One-Time Non-Cash Tax Benefit Fourth Quarter Adjusted EBITDA of $21 million, or 24% of Net Sales Management to Host Conference Call Today, February 28, 2024, at 4:30 PM ET MARIETTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the... Read More

MARIETTA, Ga., Feb. 20, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 44 th Annual Health Care Conference. TD Cowen | Boston, MA | March 4-6, 2024 Presentation: Monday, March 4, 2024 at 2:10 PM ET Webcast: Click here to access Institutional investors interested in meeting with senior management may contact their... Read More

MARIETTA, Ga., Feb. 12, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Wednesday, February 28, 2024. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern... Read More

MARIETTA, Ga., Jan. 22, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has enhanced its capital structure by refinancing its existing indebtedness and obtaining additional borrowing capacity in support of the Company’s future growth objectives. These new senior secured credit facilities (the “Facilities”), totaling $95 million and due in January 2029, are... Read More

Receipt of FDA Warning Letter for AXIOFILL Classification; Not Related to Safety Request for Designation for AXIOFILL Submitted to FDA and Currently Under Review Reiterates Expectations for 2023 Net Sales Growth in the High Teens and Fourth Quarter Adjusted EBITDA Margin of Above 20% MARIETTA, Ga., Dec. 29, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today provided the following... Read More

MARIETTA, Ga., Dec. 28, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that its outstanding 95,000 shares of Series B Convertible Preferred Stock (the “Preferred Stock”), together with any accrued dividends, were automatically converted into shares of the Company’s Common Stock on December 22, 2023, in accordance with the Preferred Stock terms set forth in the Company’s... Read More

MARIETTA, Ga., Nov. 13, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum Capital Group 14 th Annual Alpha Select Conference Thursday, November 16, 2023 Sheraton New York Times Square Hotel 811 7 th Avenue, W 53 rd St New York, NY Mizuho Medical Device & Healthcare... Read More

MARIETTA, Ga., Nov. 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced it will sponsor an Innovation Theater lunch symposium at the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place November 2-5 in Las Vegas, NV. In addition, the Company will participate in the conference’s exhibition at booth number 511. In the session, Drs. Mouawad, Tettelbach, and... Read More

Third Consecutive Quarter of Net Sales Growth Exceeding 20% Over the Prior Year Period Raises Full-Year 2023 Net Sales Percentage Growth Outlook to the High Teens MARIETTA, Ga., Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the quarter ended September 30, 2023. Recent Operating and Financial Highlights: Third quarter 2023... Read More

MARIETTA, Ga., Oct. 16, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2023 after the market close on Monday, October 30, 2023. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same... Read More

MARIETTA, Ga., Sept. 26, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIEFFECT™, the Company’s latest addition to its portfolio of AWC solutions. EPIEFFECT expands the Company’s core AWC offering for clinicians treating acute and chronic, hard-to-heal wounds such as diabetic foot ulcers (“DFUs”) and venous leg ulcers (“VLUs”), among other common... Read More

MARIETTA, Ga., Sept. 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the following investor conferences: H.C. Wainwright 25 th Annual Global Investment Conference Presentation: Tuesday, September 12, 2023 at 12:30 PM ET Webcast: Click here to access Northland Capital Markets Institutional Investor Conference (Virtual)... Read More

Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive as Chief Financial Officer Management to Host Conference Call on Tuesday, August 1, 2023, at 5:00 PM ET MARIETTA, Ga., Aug. 01, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today... Read More

MARIETTA, Ga., July 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2023 after the market close on Tuesday, August 1, 2023. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 5:00 p.m. Eastern Time on the same day.... Read More

MARIETTA, Ga., July 11, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that the Eleventh Circuit Court of Appeals affirmed the dismissal of the putative securities class action lawsuit brought against the Company and others in 2019. In the action, the plaintiff claimed that the Company violated federal securities laws. The case was on appeal from the United States... Read More

MARIETTA, Ga., July 05, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has appointed Doug Rice as the Company’s Chief Financial Officer, effective today. Pete Carlson, who has served in that role since March 2020, has resigned as Chief Financial Officer, also effective today. Mr. Rice joins MIMEDX after nearly a decade as the CFO of Orthofix Medical, a leading... Read More

Suspending Current Activities Associated with Knee Osteoarthritis Program and Disbanding Regenerative Medicine Business Unit Restructuring Expected to Generate Approximately $25 Million in Annualized Savings Raising Expectations to Deliver Mid-Teens Percentage Net Sales Growth During 2023 Management to Host Conference Call Today at 5:30pm ET to Discuss Update MARIETTA, Ga., June 20, 2023 (GLOBE NEWSWIRE) -- MiMedx Group,... Read More

First Quarter Net Sales of $71.7 Million Reflect an Increase of 21.7% Over the Prior Year Period Revenue Growth & Cost Controls Help Drive Improvements in Net Loss, EBITDA & Adjusted EBITDA 1 Management to Host Conference Call on Tuesday, May 2, 2023, at 5:00 PM ET MARIETTA, Ga., May 02, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today... Read More

MARIETTA, Ga., April 18, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the first quarter ended March 31, 2023 after the market close on Tuesday, May 2, 2023. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at... Read More

MARIETTA, Ga., March 23, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that Peter M. Carlson, Chief Financial Officer, has decided to leave the Company to pursue other opportunities. The Company has initiated a search for its next Chief Financial Officer and Mr. Carlson will be assisting MIMEDX throughout this process to... Read More

MARIETTA, Ga., March 16, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today applauded the recent report published by OIG entitled, “Some Skin Substitute Manufacturers Did Not Comply with New ASP Reporting Requirements.” The report, which can be accessed on the U.S. Department of Health and Human Services’ website , details extensive... Read More

Reports Highest Quarterly Net Sales Since the Fourth Quarter of 2019 Quarterly Net Sales of $74.4 million Reflect Growth of 10% with Strong Contributions from Sales to the Surgical Market Initiated the First of Two Registrational Clinical Trials for micronized dehydrated human amnion/chorion membrane (“mDHACM”) in the Treatment of Knee Osteoarthritis (“KOA”) Management to Host Conference Call Today, February 28, 2023, at... Read More

MARIETTA, Ga., Feb. 15, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it will report operating and financial results for the fourth quarter and full year ended December 31, 2022 after the market close on Tuesday, February 28, 2023. The MIMEDX senior management team will host a webcast and conference call to review its... Read More

Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA, Ga., Jan. 30, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that its Board of Directors has appointed Joseph H. Capper as the Company’s Chief Executive Officer and a director of the... Read More

Fourth quarter and full year 2022 net sales expected in the ranges of $73 million to $76 million and $266 million to $269 million, respectively Provides commentary regarding the potential impact of recently published Medicare reimbursement proposals on its wound care products MARIETTA, Ga., Jan. 09, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental... Read More

MIMEDX aligns with a leading distributor of wound care products in Japan to capitalize on first-mover advantage for EPIFIX MARIETTA, Ga. and OSAKA, Japan, Jan. 04, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc . (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it has entered into an exclusive distribution agreement with GUNZE MEDICAL LIMITED (“Gunze Medical”), a... Read More

MIMEDX bolsters management team with 30+ year MedTech veteran with extensive operational leadership MARIETTA, Ga., Jan. 03, 2023 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a role that will lead the efforts of the Company’s manufacturing, supply chain,... Read More